Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible.

Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, OCU410ST.

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug’s future. The Phase III study (NCT06400511) ...

Bristol Myers Squibb (BMS) has revealed that its Phase III trial assessing Reblozyl with JAKi therapy did not meet its primary goal.

Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment.

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

Velocity Clinical Research partnered with Palantir Technologies for streamlining and automating payment reconciliation processes in trials ...

UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI).

Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet its primary endpoint.

The UK MHRA has granted approval for Cybin to initiate the EMBRACE study to assess CYB003 for the adjunctive treatment of MDD.

The growing prevalence of prediabetes among children and adolescents suggests that unhealthy, inactive lifestyles are increasing in the US.